My Treatment Approach: Applying Evidence to Clinical Practice to Improve Outcomes in Differentiated Thyroid Cancer

home / insights / my-treatment-approach-applying-evidence-to-clinical-practice-to-improve-outcomes-in-dtc

Experts in the field of differentiated thyroid cancer highlight recent advances in treatment by reviewing two real-world patient scenarios.

EP. 1: Patient Profile 1: Radioiodine-Refractory Differentiated Thyroid Cancer

Marcia S. Brose, MD, PhD;Lori J. Wirth, MD;Bruce Robinson, MD

April 15th 2022

Expert Marcia Brose, MD, details a clinical scenario wherein a patient is diagnosed with differentiated thyroid cancer and managed with surgical and radiotherapy.

EP. 2: Patient Profile 1: Lenvatinib in the Treatment of RAI-Refractory DTC

Marcia S. Brose, MD, PhD;Lori J. Wirth, MD;Bruce Robinson, MD

April 15th 2022

Perspectives on the use of lenvatinib therapy to manage a patient with radioiodine-refractory DTC, preceding broader considerations for sequencing kinase inhibitor therapy.

EP. 3: Factors in Selecting Treatment for DTC

Marcia Brose, MD, PhD, FASCO;Lori J. Wirth, MD;Bruce Robinson, MD

April 22nd 2022

Reflecting on the first patient scenario of radioiodine-refractory DTC, experts share their considerations for optimally selecting and sequencing therapy in this setting.

EP. 4: Role of Endocrinologists and Oncologists in the Management of DTC

Marcia Brose, MD, PhD, FASCO;Lori J. Wirth, MD;Bruce Robinson, MD

April 22nd 2022

A brief discussion on where endocrinologists and oncologists respectively fit into the differentiated thyroid cancer treatment paradigm.

EP. 5: Optimizing the Use of Lenvatinib in DTC: Patient Selection and Dosing

Marcia Brose, MD, PhD, FASCO;Lori J. Wirth, MD;Bruce Robinson, MD

April 29th 2022

Shared insight on selecting appropriate patients for lenvatinib therapy in differentiated thyroid cancer, as well as optimizing dosing strategies in the context of clinical trial data.

EP. 6: Treatment of DTC With Lenvatinib: Managing Adverse Events

Marcia Brose, MD, PhD, FASCO;Lori J. Wirth, MD;Bruce Robinson, MD

April 29th 2022

Expert advice on addressing adverse events, particularly through dose holds or reduction, in patients on lenvatinib therapy for radioiodine-refractory DTC.

EP. 7: Patient Profile 2: Diagnosing and Assessing DTC

Marcia Brose, MD, PhD, FASCO;Lori J. Wirth, MD;Bruce Robinson, MD

May 6th 2022

Expert Lori Wirth, MD, highlights key points from a second real-world patient scenario of radioiodine-refractory differentiated thyroid cancer.

EP. 8: Defining RAI-Refractory DTC and Selecting Patients for Disease Monitoring

Lori J. Wirth, MD;Marcia Brose, MD, PhD, FASCO;Bruce Robinson, MD

May 6th 2022

Reflecting on a real-world patient scenario of DTC, experts consider how they identify radioiodine-refractory disease and when they would initiate systemic therapy.

EP. 9: Patient Surveillance and Therapy Selection in RAIR DTC

Marcia Brose, MD, PhD, FASCO;Lori J. Wirth, MD;Bruce Robinson, MD

May 13th 2022

Shared insight on active surveillance practices for patients with radioiodine-refractory DTC and how disease factors play into selection of therapy at time of recurrence.

EP. 10: Practical Advice for Community Endocrinologists and Oncologists Treating DTC

Marcia Brose, MD, PhD, FASCO;Lori J. Wirth, MD;Bruce Robinson, MD

May 13th 2022

Before closing out their discussion on radioiodine-refractory DTC management, experts share practical advice for community physicians.

EP. 11: Differentiated Thyroid Cancer: Unmet Needs and Future Directions

Marcia Brose, MD, PhD, FASCO;Lori J. Wirth, MD;Bruce Robinson, MD

May 20th 2022

Experts highlight remaining unmet needs in the management of radioiodine-refractory differentiated thyroid cancer and share their hopes for the future.